• Epalrestat in Metabolic Oncology: Beyond Aldose Reductase In

  2026-05-25

  Explore how Epalrestat, a potent aldose reductase inhibitor, is shaping metabolic oncology research by bridging oxidative stress, polyol pathway inhibition, and practical assay design. Gain a deeper understanding of its relevance for cancer, neurodegeneration, and advanced metabolic studies.

• Toremifene in Breast Cancer: 20 Years of Data and Clinical I

  2026-05-24

  This review synthesizes two decades of clinical and mechanistic data on toremifene, a selective estrogen receptor modulator, in the management of hormone-sensitive breast cancer. Key findings emphasize the drug’s efficacy, safety, and unique pharmacokinetics, contextualizing its place among endocrine therapies and highlighting the clinical importance of personalized treatment based on biomarker profiles.

• MK-2206 dihydrochloride: Precision Tools for Akt Pathway Dis

  2026-05-23

  MK-2206 dihydrochloride stands out as a selective, allosteric Akt inhibitor, empowering researchers to dissect the PI3K/Akt/mTOR axis with high specificity. Its robust solubility profile and validated efficacy in apoptosis, angiogenesis, and combination therapy models make it indispensable for translational cancer and endometriosis research.

• Isradipine (Dynacirc): Advanced Workflows for Calcium Channe

  2026-05-22

  Isradipine (Dynacirc) stands out as a robust L-type calcium channel blocker for researchers tackling questions in neuroprotection and vascular smooth muscle biology. This guide delivers actionable protocols, troubleshooting insights, and strategic comparisons to empower reproducible, high-impact experiments leveraging APExBIO's high-purity product.

• Raising the Bar: Mechanistic and Strategic Advances with EZ

  2026-05-22

  This article delivers a deep mechanistic and translational dive into the next generation of capped mRNA for CRISPR-Cas9 genome editing, with a focus on how EZ Cap™ Cas9 mRNA (m1Ψ) from APExBIO uniquely positions translational researchers for breakthroughs. Integrating recent insights on mRNA nuclear export and immune evasion, it bridges high-level mechanistic rationale, practical protocol guidance, and a competitive landscape analysis, culminating in a forward-looking synthesis for the future of genome editing workflows.

• Adipose-Neural Axis and Arrhythmia: Insights from Fan et al.

  2026-05-21

  Fan et al. (2024) present a stem cell-based coculture model that uncovers how the adipose-neural axis, particularly via leptin and the neuropeptide Y (NPY) pathway, contributes to epicardial adipose tissue-related cardiac arrhythmias. Their findings offer mechanistic insight and highlight new molecular targets for arrhythmia intervention.

• USP42 Promotes Breast Cancer Progression via JNK/p38 Inhibit

  2026-05-21

  This study demonstrates that the deubiquitinating enzyme USP42 drives breast cancer progression by suppressing JNK/p38-mediated apoptosis. The research provides mechanistic insight into how USP42 modulates cell survival pathways and suggests USP42 as a promising therapeutic target in breast cancer.

• Ceftolozane/Tazobactam: Advances Against Resistant Gram-Nega

  2026-05-20

  The reference study reviews ceftolozane/tazobactam, a novel cephalosporin/beta-lactamase inhibitor combination, highlighting its efficacy against multidrug-resistant gram-negative pathogens such as Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. Its unique pharmacodynamics and activity profile address gaps left by traditional beta-lactam agents, providing new avenues for managing complicated intraabdominal and urinary tract infections.

• Mechanistic Precision and Strategic Vision: The Future of mC

  2026-05-20

  This article examines the mechanistic advances and translational potential of EZ Cap™ mCherry mRNA (5mCTP, ψUTP), integrating state-of-the-art evidence on immune evasion, stability, and reporter fidelity. We contextualize its utility for researchers designing next-generation assays, bridge key findings from lipid nanoparticle delivery research, and provide actionable guidance for maximizing robust fluorescent protein expression with minimized immune activation.

• Iptacopan (LNP023): Precision in Complement Pathway Research

  2026-05-19

  Iptacopan (LNP023) empowers researchers with highly selective, oral inhibition of complement factor B, enabling robust modeling of alternative pathway-driven diseases. This guide details applied workflows, advanced troubleshooting, and practical innovations that set APExBIO’s Iptacopan apart for both in vitro and in vivo complement activation research.

• Norovirus Harnesses NINJ1 for Selective Viral Protein Secret

  2026-05-19

  Song et al. uncover how murine norovirus (MNoV) co-opts the cell death effector NINJ1 to mediate selective secretion of the viral NS1 protein, revealing an unconventional, regulated export mechanism. These findings illuminate a previously uncharacterized host-pathogen interaction linking cell death, protein secretion, and immune evasion.

• SERCA2 Dysfunction Drives Pulmonary Vascular Remodeling via

  2026-05-18

  This study demonstrates that SERCA2 dysfunction directly induces inflammation and oxidative stress in pulmonary artery smooth muscle cells, driving pulmonary vascular remodeling by downregulating the PPARγ/PGC1α/Nrf2 axis. The findings clarify molecular mechanisms linking calcium transport dysregulation to pulmonary hypertension pathology and nominate key redox and metabolic regulators as therapeutic targets.

• Oligomycin A: Precision Mitochondrial ATP Synthase Inhibitor

  2026-05-18

  Oligomycin A stands out as a gold-standard mitochondrial ATP synthase inhibitor, enabling robust, reproducible interrogation of bioenergetics, apoptosis, and cancer metabolic adaptation. This guide translates recent reference breakthroughs and advanced troubleshooting into actionable workflow enhancements, maximizing assay sensitivity and reliability with APExBIO’s Oligomycin A.

• Lopinavir: Repurposing an HIV Protease Inhibitor for MERS-Co

  2026-05-17

  de Wilde et al. conducted a large-scale screen of FDA-approved drugs, identifying lopinavir (ABT-378) and three other compounds as inhibitors of MERS-CoV replication in vitro. This work demonstrates the utility of drug repurposing strategies for emerging viral threats and provides a framework for further antiviral research.

• Grazoprevir Hydrate (MK-5172): Precision Workflows for HCV I

  2026-05-16

  Grazoprevir hydrate (MK-5172 hydrate) enables precise, high-efficacy hepatitis C virus (HCV) replication inhibition across challenging genotypes and patient models. This article unpacks experimental workflows, troubleshooting strategies, and key innovations, offering advanced guidance for researchers leveraging APExBIO’s trusted compound.

450 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page